Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
3,232
Views
1
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer
Caitlin Smarea HEOR, Parexel International, London, UKCorrespondence[email protected]
, Kiran Davea HEOR, Parexel International, London, UK
, Ariadna Juarez-Garciab Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Uxbridge, UK
, Pranav Abrahamc Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
, John R. Penrodc Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
, D. Ross Camidged Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, CO, USA
& Yong Yuanc Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
show all
Pages 1124-1133
|
Received 15 Sep 2020, Accepted 27 Aug 2021, Published online: 30 Sep 2021
Related Research Data
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.